Auxiliary pharmaceutical composition for chemoradiotherapy of newly-diagnosed glioblastoma
A technology for glioblastoma and composition, applied in the field of biomedicine, can solve the problem of unclear mechanism of action, and achieve the effect of significant therapeutic effect and good application prospect.
Pending Publication Date: 2021-11-02
WEST CHINA HOSPITAL SICHUAN UNIV
View PDF1 Cites 0 Cited by
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Clinical studies have found that apatinib combined with TMZ in the treatment of recurrent GBM is superior to TMZ alone, and patients benefit from PFS, ORR, and DCR, and the side effects are controllable. Mechanism unknown
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View moreImage
Smart Image Click on the blue labels to locate them in the text.
Smart ImageViewing Examples
Examples
Experimental program
Comparison scheme
Effect test
Embodiment
[0014] An adjuvant drug composition for newly diagnosed glioblastoma in radiotherapy and chemotherapy, used for postoperative synchronous radiochemotherapy for newly diagnosed glioblastoma, and taken at the same time as chemotherapy.
[0015] The pharmaceutical composition includes: a combination of two separate reagents, temozolomide (TMZ for short) and apatinib mesylate, wherein the ratio of apatinib mesylate to temozolomide is 1:1.25, and in each pharmaceutical composition The content of apatinib mesylate is 250mg.
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More PUM
Login to View More Abstract
The invention relates to an auxiliary pharmaceutical composition for chemoradiotherapy of newly-diagnosed glioblastoma, which is used for postoperative synchronous chemoradiotherapy of the newly-diagnosed glioblastoma, is taken during chemotherapy, and comprises a combination of two independent reagents, namely temozolomide and apatinib mesylate. by using the auxiliary pharmaceutical composition, the treatment effect of newly diagnosed glioblastoma is improved, and a new strategy and thought are provided for treatment of glioma.
Description
technical field [0001] The invention belongs to the field of biomedicine, and relates to an auxiliary drug composition used in radiotherapy and chemotherapy of newly diagnosed glioblastoma. Background technique [0002] Glioma (GBM) is a malignant tumor with poor prognosis, and the existing treatment measures are very limited, so it is of great significance to explore new treatment strategies for GBM. Tumor field therapy (TTF) is a new type of anti-cancer therapy, which interferes with the mitosis of tumor cells by applying a low-intensity medium-frequency alternating electric field to the local area of the tumor, inhibits the proliferation of tumor cells, and leads to apoptosis of tumor cells. [0003] Temozolomide (TMZ) is an oral alkylating agent that can pass through the blood-brain barrier and directly reach the lesion. It is one of the first-line commonly used drugs for clinical chemotherapy of glioma. Impaired DNA alkylation will produce cross-linking after DNA a...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More Application Information
Patent Timeline
Login to View More IPC IPC(8): A61K31/444A61P35/00A61K31/4188
CPCA61K31/444A61K31/4188A61P35/00A61K2300/00
Inventor 王峰谢筱琪
Owner WEST CHINA HOSPITAL SICHUAN UNIV
PatSnap Eureka turns technology decisions into work you can execute. Powered by our Innovation Knowledge Graph, it runs expert workflows across engineering, life sciences, materials and intellectual property. Get your review-ready output in minutes.
